Viridian Poised to Challenge Horizon in Thyroid Eye Disease
Early-stage data shows that Viridian’s thyroid eye disease candidate induces clinically meaningful improvements in eye protrusion after six weeks of treatment.
Source: biospace.com
Kimberly Cockerham News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Kimberly Cockerham. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Kimberly Cockerham Today - Breaking & Trending Today
Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED)
- VRDN-001 data demonstrated clinically meaningful and rapid improvement in signs and symptoms of chronic TED at week 6 after receiving two infusions of VRDN-001 10 mg/kg or 3 mg/kg – - Ongoing THRIVE Phase 3 trial in patients with active TED amended to reflect Viridian’s confidence in 5-dose regimen and key stakeholder feedback on evolving TED treatment paradigm - - THRIVE-2 Phase 3 trial in patients with chronic TED expected to start in third quarter 2023 – - 3 mg/kg data support low-volume subcutaneous (SC) dosing profile for Company’s SC candidates in TED - - Viridi...
Source: marketscreener.com